应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
02196 复星医药
未开盘 08-18 16:08:05
16.880
-0.080
-0.47%
最高
17.200
最低
16.860
成交量
193.97万
今开
17.020
昨收
16.960
日振幅
2.00%
总市值
448.84亿
流通市值
91.32亿
总股本
26.59亿
成交额
3,302万
换手率
0.36%
流通股本
5.41亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
财报前瞻｜复星医药本季度营收预计增8.56%，机构普遍看多盈利修复
财报Agent · 08-18 08:20
财报前瞻｜复星医药本季度营收预计增8.56%，机构普遍看多盈利修复
复星医药子公司携生物类似药出海 牵手全球仿制药龙头，锁定四成销售分成
每日经济新闻 · 08-17 17:26
复星医药子公司携生物类似药出海 牵手全球仿制药龙头，锁定四成销售分成
复星医药(02196.HK)控股子公司复宏汉霖与Sandoz AG签订合作框架协议并达成许可
智通财经 · 08-17 08:34
复星医药(02196.HK)控股子公司复宏汉霖与Sandoz AG签订合作框架协议并达成许可
复星医药子公司复宏汉霖携手Sandoz 首批三款生物类似药海外授权潜在总对价最高2.37亿美元
公告速递 · 08-17 08:26
复星医药子公司复宏汉霖携手Sandoz 首批三款生物类似药海外授权潜在总对价最高2.37亿美元
复星医药拟与山德士合作，共同推进多达10款生物药的商业化、开发与生产
美股速递 · 08-17 08:03
复星医药拟与山德士合作，共同推进多达10款生物药的商业化、开发与生产
复星医药(600196.SH)子公司签订合作框架协议并达成许可
智通财经 · 08-17 07:57
复星医药(600196.SH)子公司签订合作框架协议并达成许可
【券商聚焦】中信建投：AI制药大有可为，产业链有望持续受益
金吾财讯 · 08-14
【券商聚焦】中信建投：AI制药大有可为，产业链有望持续受益
复星医药（02196）将于8月25日召开董事会审议2026年中期业绩
公告速递 · 08-13
复星医药（02196）将于8月25日召开董事会审议2026年中期业绩
每周股票复盘：复星医药（600196）多款新药获批
证券之星 · 08-09
每周股票复盘：复星医药（600196）多款新药获批
复星医药：控股子公司药品获注册批准
公告速递 · 08-07
复星医药：控股子公司药品获注册批准
复星医药(02196.HK)：盐酸左沙丁胺醇雾化吸入溶液获注册批准
智通财经 · 08-07
复星医药(02196.HK)：盐酸左沙丁胺醇雾化吸入溶液获注册批准
复星医药控股子公司一款5 ml:100 mg规格药品获注册批准
公告速递 · 08-07
复星医药控股子公司一款5 ml:100 mg规格药品获注册批准
盐酸多巴酚丁胺注射液药品注册申请获国家药监局批准——复星医药
美股速递 · 08-07
盐酸多巴酚丁胺注射液药品注册申请获国家药监局批准——复星医药
复星医药：复星高科技解除1.57亿股A股质押 质押比例降至13.72%
公告速递 · 08-07
复星医药：复星高科技解除1.57亿股A股质押 质押比例降至13.72%
复星医药：控股股东复星高科技解除质押1.57亿股
南方财经网 · 08-07
复星医药：控股股东复星高科技解除质押1.57亿股
复星医药最新公告：子公司盐酸左沙丁胺醇雾化吸入溶液获注册批准
证券之星 · 08-07
复星医药最新公告：子公司盐酸左沙丁胺醇雾化吸入溶液获注册批准
复星医药（600196）披露截至2026年7月31日证券变动月报表，8月6日股价下跌0.83%
证券之星 · 08-06
复星医药（600196）披露截至2026年7月31日证券变动月报表，8月6日股价下跌0.83%
复星医药7月股份变动月报表，股本维持稳定
公告速递 · 08-06
复星医药7月股份变动月报表，股本维持稳定
复星医药（02196）控股子公司糖尿病复方缓释片获国家药监局注册批准
公告速递 · 08-03
复星医药（02196）控股子公司糖尿病复方缓释片获国家药监局注册批准
复星医药(02196.HK)：恩格列净二甲双胍缓释片(III)获注册批准
智通财经 · 08-03
复星医药(02196.HK)：恩格列净二甲双胍缓释片(III)获注册批准
加载更多
公司概况
公司名称：
复星医药
所属市场：
SEHK
上市日期：
--
主营业务：
上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司通过五个分部开展业务。制药分部主要从事药品的研发、生产和销售。医疗器械与医学诊断分部主要从事医疗器械和诊断产品的研发、生产和销售。医疗健康服务分部主要从事提供医疗健康服务及医院管理。医药分销和零售分部主要从事医药、器械分销和零售。 该公司还运营其他分部。该公司主要在中国国内和海外市场开展业务。
发行价格：
--
{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":16.88,"timestamp":1787040485004,"preClose":16.96,"halted":0,"volume":1939744,"delay":0,"changeRate":-0.004716981132075581,"floatShares":540971500,"shares":2659000000,"eps":1.4764254284481744,"marketStatus":"未开盘","change":-0.08,"latestTime":"08-18 16:08:05","open":17.02,"high":17.2,"low":16.86,"amount":33017810,"amplitude":0.020047,"askPrice":16.89,"askSize":2500,"bidPrice":16.88,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":1.5227665862661282,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787103000000},"marketStatusCode":0,"adr":0,"listingDate":1351526400000,"exchange":"SEHK","adjPreClose":16.96,"dividendRate":0.026889,"openAndCloseTimeList":[[1787016600000,1787025600000],[1787029200000,1787040000000]],"volumeRatio":0.7422870785696922,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":24.03,"timestamp":1787036400000,"preClose":24.01,"halted":0,"volume":28453400,"delay":0,"premium":"-39.58"}},"requestUrl":"/m/hq/s/02196","defaultTab":"news","newsList":[{"id":"1147572498","title":"财报前瞻｜复星医药本季度营收预计增8.56%，机构普遍看多盈利修复","url":"https://stock-news.laohu8.com/highlight/detail?id=1147572498","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147572498?lang=zh_cn&edition=full","pubTime":"2026-08-18 08:20","pubTimestamp":1787012456,"startTime":"0","endTime":"0","summary":"复星医药将于2026年08月25日发布财报，市场预计营收延续中单位数增长，盈利能力温和修复，关注制药主业与创新管线的费用与转化效率。上季度公司实现营收99.99亿元，同比增长6.14%；毛利率49.70%；归属于母公司股东的净利润为8.71亿元，净利率8.64%；调整后每股收益为0.33元，同比增长13.79%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜复星医药本季度营收预计增8.56%，机构普遍看多盈利修复","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660866704","title":"复星医药子公司携生物类似药出海 牵手全球仿制药龙头，锁定四成销售分成","url":"https://stock-news.laohu8.com/highlight/detail?id=2660866704","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660866704?lang=zh_cn&edition=full","pubTime":"2026-08-17 17:26","pubTimestamp":1786958770,"startTime":"0","endTime":"0","summary":"8月17日，复星医药（SH600196，股价24.01元，市值588.9亿元）公告披露，其控股子公司复宏汉霖与全球生物类似药龙头SandozAG于8月16日签订《合作框架协议》。双方约定，可就复宏汉霖至多10款单克隆抗体（mAb）和/或抗体偶联药物（ADC）生物类似药，开展海外区域的注册、商业化、开发、生产等许可合作，并已就首批3款产品达成具体商业条款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173843260444.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173843260444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","BK0096","BK0187","600196","XPH","LU2272731865.HKD","BK0060","LU2272731782.SGD","BK0239","BK0028","BK1593","LU1992135472.HKD","BK1191","02196","BK4588","LU2473716301.USD","BK0012","LU2322448791.USD","BK0183","BK0175","LU2322448957.HKD","BK0196","PPH","IE00B5TLWC47.USD","BK1515","IBB","BK4585","LU2272731600.USD","LU1992135399.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660059911","title":"复星医药(02196.HK)控股子公司复宏汉霖与Sandoz AG签订合作框架协议并达成许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2660059911","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660059911?lang=zh_cn&edition=full","pubTime":"2026-08-17 08:34","pubTimestamp":1786926890,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","HK0000306685.HKD","02696","BK1191","HK0000165453.HKD","HK0000306701.USD","BK1593","HK0000320223.HKD","02196","HK0000320264.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178686437","title":"复星医药子公司复宏汉霖携手Sandoz 首批三款生物类似药海外授权潜在总对价最高2.37亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1178686437","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178686437?lang=zh_cn&edition=full","pubTime":"2026-08-17 08:26","pubTimestamp":1786926405,"startTime":"0","endTime":"0","summary":"2026年8月17日，复星医药公告称，其控股子公司上海复宏汉霖生物技术股份有限公司已于2026年8月16日与Sandoz AG签订《合作框架协议》，计划就最多10款单克隆抗体及/或抗体偶联药物生物类似药在海外相关区域开展注册、商业化、开发和生产等合作。首批合作产品包括HLX05-N、HLX16及贝利尤单抗生物类似药；复宏汉霖同时向Sandoz AG授予对HLXTE-HAase1001的选择权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129073878","title":"复星医药拟与山德士合作，共同推进多达10款生物药的商业化、开发与生产","url":"https://stock-news.laohu8.com/highlight/detail?id=1129073878","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129073878?lang=zh_cn&edition=full","pubTime":"2026-08-17 08:03","pubTimestamp":1786924988,"startTime":"0","endTime":"0","summary":"复星医药宣布，计划与山德士携手，围绕多达10款生物制品展开合作。合作范围涵盖商业化、开发以及生产等关键环节。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600196","BK0012","BK0028","BK0188","BK0060","BK1515","BK1191","BK0187","BK0175","BK1593","BK0096","BK0183","BK0196","BK0239","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660103095","title":"复星医药(600196.SH)子公司签订合作框架协议并达成许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2660103095","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660103095?lang=zh_cn&edition=full","pubTime":"2026-08-17 07:57","pubTimestamp":1786924663,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，2026年8月16日，公司控股子公司复宏汉霖与Sandoz AG签订《合作框架协议》，将可就复宏汉霖至多10款单克隆抗体和/或抗体偶联药物生物类似药产品或成分与Sandoz AG开展海外相关区域的注册、商业化、开发、生产等许可合作，并已就首批3款合作产品达成具体商业条款、1款潜在合作产品向Sandoz AG授出选择权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480502.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","600196","BK0188","BK0096","BK0239","BK1515","BK1593","BK0012","02196","BK0175","BK0187","BK1191","BK0060","BK0028","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659199950","title":"【券商聚焦】中信建投：AI制药大有可为，产业链有望持续受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2659199950","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659199950?lang=zh_cn&edition=full","pubTime":"2026-08-14 08:58","pubTimestamp":1786669118,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指出，AI制药领域正经历着快速的迭代和变革，算法的更新迭代和算力的支持为AI在制药领域的应用打下了良好的基础。传统药物开发过程花费时间长成本高，且成功率较低，随着已有靶点的新药陆续获批，新药开发难度逐渐上升。近年来AI特别是深度学习的发展，促进了其在包括靶点筛选、分子生成及优化、ADMET预测、晶型预测以及合成路线筛选等的应用，AI用于大分子药物的开发投入也持续增长。AIDD有望重塑早期药物发现的流程，大大加速早期药物筛选的效率及成功率，相关干实验投入的增加以及对湿实验需求持续的增长，有望为下游产业链持续带来增量。","market":"us","thumbnail":"https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988188","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1719994722.HKD","LU2476274308.USD","LU0417516571.SGD","01530","LU1303224171.USD","LU1770034418.SGD","LU2778985437.USD","09926","601066","02367","06821","AGIX","LU0640798160.USD","QTOC","LU2476274720.SGD","LU0348827113.USD","LU1961090484.USD","BK1197","01477","01789","BK1515","01099","CHAT","SG9999004311.SGD","03933","LU0417516738.SGD","AIPO","02196","LU0634319403.HKD","LU0348735423.USD","BK1585","LU0828237510.HKD","LU0348784397.USD","09688","02228","KCE","LU2328871848.SGD","BK1191","VTHR","LU0348766576.USD","06160","ARTY","KURE","BK1500","IE00B5MMRT66.SGD","LU0348783233.USD","LU0348825331.USD","LU0540923850.HKD","LU0561508036.HKD","02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131470914","title":"复星医药（02196）将于8月25日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1131470914","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131470914?lang=zh_cn&edition=full","pubTime":"2026-08-13 16:37","pubTimestamp":1786610270,"startTime":"0","endTime":"0","summary":"复星医药（02196）8月13日公告，公司董事会已排期于2026年8月25日（星期二）召开会议，届时将审议并通过公司及其附属公司截至2026年6月30日止六个月的中期业绩，并于会后予以刊发。\n公告显示，董事会主席陈玉卿以董事会名义发布该通知。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658867361","title":"每周股票复盘：复星医药（600196）多款新药获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2658867361","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658867361?lang=zh_cn&edition=full","pubTime":"2026-08-09 01:21","pubTimestamp":1786209670,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，复星医药报收于23.75元，较上周的23.23元上涨2.24%。本周关注点公司公告汇总：复星医药旗下四款新药相继获批上市。股本股东变化截至2026年8月6日收市，控股股东复星高科技持有复星医药约36.00%股份，本次解除质押157,000,000股A股，占其所持股份的16.33%，占公司总股本的5.88%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","02196","BK0175","600196","BK1593","BK0188","BK0012","BK0096","BK0187","BK0196","BK0239","BK0183","BK0028","BK1515","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156540967","title":"复星医药：控股子公司药品获注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1156540967","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156540967?lang=zh_cn&edition=full","pubTime":"2026-08-07 20:22","pubTimestamp":1786105331,"startTime":"0","endTime":"0","summary":"2026年8月7日，复星医药（02196）公告称，其控股子公司的一款药品已取得注册批准。该产品规格为3 ml:0.63 mg，获批文号为H20265490。 \n \n复星医药表示，此次获批将有助于相关产品在国内市场的销售与推广。根据公告引用的IQVIA CHPA数据，2025年该产品对应市场规模为0.73（单位详见公告）。 \n \n公司指出，上述事项对其当期经营业绩的影响尚存在不确定性，后续将按监管要求及时披露相关进展。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657383645","title":"复星医药(02196.HK)：盐酸左沙丁胺醇雾化吸入溶液获注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2657383645","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657383645?lang=zh_cn&edition=full","pubTime":"2026-08-07 20:19","pubTimestamp":1786105199,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","BK1515","02196","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179100860","title":"复星医药控股子公司一款5 ml:100 mg规格药品获注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1179100860","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179100860?lang=zh_cn&edition=full","pubTime":"2026-08-07 20:10","pubTimestamp":1786104637,"startTime":"0","endTime":"0","summary":"2026年8月7日，复星医药（02196）发布公告称，其控股子公司有一款药品获得注册批准。以下为公告披露的主要信息：\n1. 批准信息 \n• 批准文号：H20265441 \n• 药品规格：5 ml:100 mg \n• 分子式：C₁₈H₂₃NO₃\n2. 市场概况 \n• 公告援引IQVIA CHPA数据显示，2025年相关市场规模为0.79（公告未披露具体单位）。\n3. 其他事项 \n• 公司表示，药品获得注册批准后，将根据后续生产及市场推广情况对公司经营业绩产生的影响进行评估。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162670165","title":"盐酸多巴酚丁胺注射液药品注册申请获国家药监局批准——复星医药","url":"https://stock-news.laohu8.com/highlight/detail?id=1162670165","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162670165?lang=zh_cn&edition=full","pubTime":"2026-08-07 20:05","pubTimestamp":1786104308,"startTime":"0","endTime":"0","summary":"复星医药传来重磅消息：其盐酸多巴酚丁胺注射液的药品注册申请，已正式获得国家药品监督管理局的批准。这一进展，标志着公司在心血管药物领域的布局又迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0012","BK0175","BK1515","BK0096","02196","600196","BK0028","BK0183","BK0060","BK1191","BK0187","BK0239","BK0196","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158490502","title":"复星医药：复星高科技解除1.57亿股A股质押 质押比例降至13.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=1158490502","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158490502?lang=zh_cn&edition=full","pubTime":"2026-08-07 19:56","pubTimestamp":1786103775,"startTime":"0","endTime":"0","summary":"2026年8月7日，复星医药公告称，其控股股东上海复星高科技（集团）有限公司于2026年8月6日解除质押公司1.57亿股A股，占其所持股份的16.33%，占公司当日股本总数的5.88%。截至2026年8月6日收市，复星高科技持有复星医药共9.61亿股，占公司总股本的36.00%。此次解押后，复星高科技所持被质押股份余额降至3.66亿股A股，占其持股的38.10%，占公司总股本的13.72%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657864876","title":"复星医药：控股股东复星高科技解除质押1.57亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657864876","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657864876?lang=zh_cn&edition=full","pubTime":"2026-08-07 19:40","pubTimestamp":1786102824,"startTime":"0","endTime":"0","summary":"南财智讯8月7日电，复星医药公告，公司于2026年8月7日接到控股股东上海复星高科技(集团)有限公司通知，其已于2026年8月6日办结所持公司157000000股A股股份的解除质押手续。本次解除质押股份数量为1.57亿股，占其所持公司股份总数的16.33%，占公司股份总数的5.88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608073835369161.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608073835369161.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","BK0060","BK0196","BK0239","BK0096","BK0175","02196","BK0012","BK1515","BK0028","BK0187","BK0188","BK1593","BK1191","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657487606","title":"复星医药最新公告：子公司盐酸左沙丁胺醇雾化吸入溶液获注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2657487606","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657487606?lang=zh_cn&edition=full","pubTime":"2026-08-07 19:39","pubTimestamp":1786102793,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，公司控股子公司复星医药(徐州)有限公司的盐酸左沙丁胺醇雾化吸入溶液药品注册申请获国家药监局批准，用于治疗或预防成人及6岁以上儿童可逆性气道阻塞性疾病引起的支气管痉挛。该药品为本集团自主研发的化学药品，截至2026年6月累计研发投入约566万元。2025年该药品在中国境内销售额约0.73亿元。本次获批将丰富公司产品线，但药品销售受多重因素影响，存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700036021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0183","BK0188","BK1515","600196","BK0196","BK0239","BK0096","BK1593","BK1191","02196","BK0060","BK0012","BK0028","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657672630","title":"复星医药（600196）披露截至2026年7月31日证券变动月报表，8月6日股价下跌0.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657672630","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657672630?lang=zh_cn&edition=full","pubTime":"2026-08-06 22:16","pubTimestamp":1786025780,"startTime":"0","endTime":"0","summary":"截至2026年8月6日收盘，复星医药报收于22.76元，较前一交易日下跌0.83%，最新总市值为607.79亿元。该股当日开盘22.96元，最高23.07元，最低22.69元，成交额达4.18亿元，换手率为0.86%。近日，上海复星医药(集团)股份有限公司披露截至2026年7月31日的证券变动月报表。公告显示，公司法定股本无变动，H股和A股的已发行股份及库存股数量与上月结存一致。H股类别中，已发行股份为540,971,500股，库存股为10,969,000股；A股类别中，已发行股份为2,098,582,573股，库存股为19,906,252股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600039846.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0175","BK0188","BK1593","161027","BK1191","BK0060","BK1515","600196","02196","BK0028","BK0096","BK0196","BK0012","BK0183","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141469549","title":"复星医药7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1141469549","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141469549?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:21","pubTimestamp":1786004468,"startTime":"0","endTime":"0","summary":"上海复星医药于2026年8月6日发布截至2026年7月31日止的证券变动月报表。公告显示，公司法定注册股本为人民币2,670,429,325元，其中包括普通H股551,940,500股与普通A股2,118,488,825股，面值均为人民币1元。本月报告期内，上述股本数量未发生变动。公司当月未发生新增发行、回购或注销股份等情况，股本规模保持稳定。公司于2025年10月通过的2025年H股受限制股份单位计划当月同样未发生新增发股或库存股转让，目前已授出但尚未归属的相关受限制股份单位为10,382,200份。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164558715","title":"复星医药（02196）控股子公司糖尿病复方缓释片获国家药监局注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1164558715","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164558715?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:46","pubTimestamp":1785750377,"startTime":"0","endTime":"0","summary":"2026年8月3日，上海复星医药（集团）股份有限公司公告称，其控股子公司复星万邦（江苏）医药集团有限公司提交的恩格列净二甲双胍缓释片获国家药品监督管理局批准注册，批准文号为“国药准字 H20265383”。规格为恩格列净12.5 mg与盐酸二甲双胍1,000 mg，注册分类为化学药品3类，上市许可持有人及生产企业均为复星万邦（江苏）医药集团有限公司。\\n\\n公告显示，截至2026年6月，该药品累计研发投入约人民币1,792万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656528327","title":"复星医药(02196.HK)：恩格列净二甲双胍缓释片(III)获注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2656528327","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656528327?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:43","pubTimestamp":1785750224,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02196","BK1515","BK1593"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":-0.0117},{"period":"1month","weight":0.0407},{"period":"3month","weight":-0.0181},{"period":"6month","weight":-0.1575},{"period":"1year","weight":-0.192},{"period":"ytd","weight":-0.1131}],"compareEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":0.037},{"period":"3month","weight":-0.007},{"period":"6month","weight":-0.0462},{"period":"1year","weight":0.0117},{"period":"ytd","weight":-0.0062}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司通过五个分部开展业务。制药分部主要从事药品的研发、生产和销售。医疗器械与医学诊断分部主要从事医疗器械和诊断产品的研发、生产和销售。医疗健康服务分部主要从事提供医疗健康服务及医院管理。医药分销和零售分部主要从事医药、器械分销和零售。 该公司还运营其他分部。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044495},{"month":2,"riseRate":0.714286,"avgChangeRate":0.036179},{"month":3,"riseRate":0.571429,"avgChangeRate":0.044259},{"month":4,"riseRate":0.357143,"avgChangeRate":0.026},{"month":5,"riseRate":0.428571,"avgChangeRate":0.024935},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.032656},{"month":7,"riseRate":0.642857,"avgChangeRate":0.03393},{"month":8,"riseRate":0.357143,"avgChangeRate":-0.036686},{"month":9,"riseRate":0.461538,"avgChangeRate":0.011613},{"month":10,"riseRate":0.461538,"avgChangeRate":0.020365},{"month":11,"riseRate":0.428571,"avgChangeRate":0.034477},{"month":12,"riseRate":0.428571,"avgChangeRate":0.015129}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}